DUBLIN – Enterprise Therapeutics Ltd. raised £29 million (US$41 million) in a series B round to take forward a pipeline of preclinical drug development programs that focus on impaired mucociliary clearance, a pathophysiological mechanism common to chronic respiratory diseases such as cystic fibrosis, chronic obstructive pulmonary disease and severe asthma.